Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results
Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 ey...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2017-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2017/6835782 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551934817468416 |
|---|---|
| author | Pedro Neves Cardoso Ana Fernanda Pinheiro Jorge Meira Ana Catarina Pedrosa Manuel S. Falcão João Pinheiro-Costa Fernando Falcão-Reis Ângela M. Carneiro |
| author_facet | Pedro Neves Cardoso Ana Fernanda Pinheiro Jorge Meira Ana Catarina Pedrosa Manuel S. Falcão João Pinheiro-Costa Fernando Falcão-Reis Ângela M. Carneiro |
| author_sort | Pedro Neves Cardoso |
| collection | DOAJ |
| description | Purpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p<0.005) between the first and third year. Conclusion. Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved. |
| format | Article |
| id | doaj-art-250c1158732a4133a8e5c5da5e437c7e |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2017-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-250c1158732a4133a8e5c5da5e437c7e2025-02-03T05:59:53ZengWileyJournal of Ophthalmology2090-004X2090-00582017-01-01201710.1155/2017/68357826835782Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term ResultsPedro Neves Cardoso0Ana Fernanda Pinheiro1Jorge Meira2Ana Catarina Pedrosa3Manuel S. Falcão4João Pinheiro-Costa5Fernando Falcão-Reis6Ângela M. Carneiro7Department of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, PortugalFaculty of Medicine, University of Porto, Porto, PortugalDepartment of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, PortugalDepartment of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, PortugalFaculty of Medicine, University of Porto, Porto, PortugalDepartment of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, PortugalDepartment of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, PortugalDepartment of Ophthalmology, Centro Hospitalar de São João, University of Porto, Porto, PortugalPurpose. To report the long-term clinical outcomes after switching from intravitreal bevacizumab or ranibizumab to aflibercept therapy in eyes with AMD. Methods. Retrospective analysis of changes in BCVA, SD-OCT image, and frequency of injections after 1, 2, and 3 years of follow-up. Results. 164 eyes were analyzed, 101 eyes switched from bevacizumab (group 1) and 63 from ranibizumab (group 2). One year after the switch, there was an overall nonsignificant mean decrease of 2 ETDRS letters in BCVA. Three years after, there was an overall mean decrease of 7 ETDRS letters, which was statistically significant. A significant improvement in the mean CRT was found at 1, 2, and 3 years. There was a significant decrease in the mean number of injections per year (7.8 to 6.5, p<0.005) between the first and third year. Conclusion. Aflibercept can be useful in the management of refractory neovascular AMD, with a good morphological response. However, in the long-term, BCVA stabilization was not achieved.http://dx.doi.org/10.1155/2017/6835782 |
| spellingShingle | Pedro Neves Cardoso Ana Fernanda Pinheiro Jorge Meira Ana Catarina Pedrosa Manuel S. Falcão João Pinheiro-Costa Fernando Falcão-Reis Ângela M. Carneiro Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results Journal of Ophthalmology |
| title | Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results |
| title_full | Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results |
| title_fullStr | Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results |
| title_full_unstemmed | Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results |
| title_short | Switch to Aflibercept in the Treatment of Neovascular AMD: Long-Term Results |
| title_sort | switch to aflibercept in the treatment of neovascular amd long term results |
| url | http://dx.doi.org/10.1155/2017/6835782 |
| work_keys_str_mv | AT pedronevescardoso switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT anafernandapinheiro switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT jorgemeira switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT anacatarinapedrosa switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT manuelsfalcao switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT joaopinheirocosta switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT fernandofalcaoreis switchtoafliberceptinthetreatmentofneovascularamdlongtermresults AT angelamcarneiro switchtoafliberceptinthetreatmentofneovascularamdlongtermresults |